BioSpace News Archive

BioCapital

Live from ASH 2022 | Ascentage Pharma Delivers Oral Presentations on Chinese Studies of Olverembatinib (HQP1351) at the ASH Annual Meeting for the Fifth Year, with Data Further Validating the Drug’s Long-Term Efficacy and Safety

Ascentage Pharma announced that it has delivered two Oral Presentations on Chinese studies of the company’s novel drug candidate olverembatinib at the American Society of Hematology 64th Annual Meeting and Exposition.

December 11, 2022
·
16 min read
Genetown

Blueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis

Blueprint Medicines Corporation announced AYVAKIT® data showing high, durable response rates and prolonged overall survival in patients with advanced systemic mastocytosis, including SM with an associated hematological neoplasm.

December 11, 2022
·
15 min read
Biotech Beach

Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma

Kite, a Gilead Company, announced findings from two new analyses of the landmark ZUMA-7 trial of Yescarta®, the largest and longest follow-up of a CAR T-cell therapy versus standard of care in patients with relapsed or refractory large B-cell lymphoma.

December 11, 2022
·
20 min read
Genetown

Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. reported new data from the ongoing extension study assessing the long-term efficacy and safety of PYRUKYND® in adults with pyruvate kinase deficiency who had participated in one of the pivotal studies, ACTIVATE and ACTIVATE-T, conducted in not regularly transfused and regularly transfused adults with PK deficiency, respectively.

December 11, 2022
·
12 min read
Drug Development

Ajax Therapeutics Presents Preclinical Data on AJ1-10502, a Next Generation Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting

Ajax Therapeutics, Inc. announced the presentation of preclinical data on the company’s next generation Type II JAK2 inhibitor, AJ1-10502, at a poster session held today at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans.

December 11, 2022
·
4 min read
Genetown

Cimeio Therapeutics Presents SCIP Platform Proof-of-Concept Data at ASH

Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, presented data for its CD117 and CD123 Shielded Cell & Immunotherapy Pairs program during this weekend’s American Society of Hematology meeting in New Orleans.

December 11, 2022
·
3 min read